ENDOCRINOLOGY LABORATORY

AstraZeneca and Amgen's TEZSPIRE showed significant reduction in nasal polyps and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering a potential new treatment option for patients.

TEZSPIRE (tezepelumab) showed significant reduction in nasal polyp size and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering potential new treatment.

The Phase III WAYPOINT trial showed AstraZeneca and Amgen’s Tezspire significantly reduced nasal polyp size and congestion in chronic rhinosinusitis patients, offering a potential new treatment option.

Positive Phase 3 WAYPOINT trial results show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients, compared to placebo, with a consistent safety profile.

Positive top-line results from the Phase 3 WAYPOINT trial show TEZSPIRE® (tezepelumab-ekko) significantly reduces nasal polyp size and nasal congestion in chronic rhinosinusitis with nasal polyps (CRSwNP) patients compared to placebo, with a consistent safety profile.

Tezspire (tezepelumab) showed significant reduction in nasal polyps and congestion in Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP), offering a potential new treatment option.

Virginia cancer centers offer advanced care, including NCI-designated comprehensive centers, updated technology, and expanding facilities, ensuring patients need not travel out of state for treatment.